---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230348"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:41:59.453236+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme to acquire Elektrofi for $750M upfront plus up to $150M in milestones

## Summary
- Halozyme will pay $750M cash upfront for Elektrofi, subject to customary adjustments for debt, cash, expenses, and net working capital.
- Up to three $50M milestone payments conditional on separate product regulatory approvals.
- Reverse termination fee of $36M payable by Halozyme if agreement terminated under certain circumstances.
- Transaction expected to close within 12 months, subject to HSR and other customary closing conditions.
- Certain employee options assumed and converted into Halozyme options, reducing cash consideration.

## SEC filing metadata
- accession: 0001193125-25-230348
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312525230348/0001193125-25-230348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312525230348/d807496d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230348
- JSON: https://secwatch.observer/filing/0001193125-25-230348.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.